Short-course treatment for community-acquired pneumonia in adults aged less than 65 years in Japan: A descriptive study using large healthcare claims database

IF 1.9 4区医学 Q3 INFECTIOUS DISEASES

Journal of Infection and Chemotherapy Pub Date : 2025-04-08 DOI:10.1016/j.jiac.2025.102698

Mikiyasu Sakai , Takamasa Sakai , Fumiko Ohtsu

{"title":"Short-course treatment for community-acquired pneumonia in adults aged less than 65 years in Japan: A descriptive study using large healthcare claims database","authors":"Mikiyasu Sakai , Takamasa Sakai , Fumiko Ohtsu","doi":"10.1016/j.jiac.2025.102698","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>In community-acquired pneumonia (CAP), short-course treatment is not inferior in effectiveness compared to conventional treatment durations, and clinical guidelines recommend 5–7-day-long treatments. However, it remains unclear how widely this practice is adopted in Japan. This study aimed to clarify the treatment duration of CAP in Japan using a large healthcare claims database.</div></div><div><h3>Methods</h3><div>We used health insurance claims data provided by JMDC Inc. (Tokyo, Japan) and included patients aged 18–64 years diagnosed with CAP who began antibiotic treatment between January 1, 2013, and December 31, 2022. Short-course treatment was defined as ≤ 7 d. Analyses were conducted separately for inpatient and outpatient cases, and the annual trends were also investigated.</div></div><div><h3>Results</h3><div>Overall, 25,572 patients (3367 inpatients and 22,205 outpatients) were included in the analysis. Short-course treatment was administered to 1087 (32 %) inpatients and 15,614 (70 %) outpatients. The proportion of short-course treatments during the 10-year study period was 31–35 % for inpatient cases and 67–72 % for outpatient cases, with no marked changes over the years.</div></div><div><h3>Conclusions</h3><div>The proportion of inpatients receiving short-course treatments for CAP was low. In Japan, especially for inpatient cases, further efforts are required to optimize the duration of CAP treatment.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 5","pages":"Article 102698"},"PeriodicalIF":1.9000,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1341321X25000959","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

In community-acquired pneumonia (CAP), short-course treatment is not inferior in effectiveness compared to conventional treatment durations, and clinical guidelines recommend 5–7-day-long treatments. However, it remains unclear how widely this practice is adopted in Japan. This study aimed to clarify the treatment duration of CAP in Japan using a large healthcare claims database.

Methods

We used health insurance claims data provided by JMDC Inc. (Tokyo, Japan) and included patients aged 18–64 years diagnosed with CAP who began antibiotic treatment between January 1, 2013, and December 31, 2022. Short-course treatment was defined as ≤ 7 d. Analyses were conducted separately for inpatient and outpatient cases, and the annual trends were also investigated.

Results

Overall, 25,572 patients (3367 inpatients and 22,205 outpatients) were included in the analysis. Short-course treatment was administered to 1087 (32 %) inpatients and 15,614 (70 %) outpatients. The proportion of short-course treatments during the 10-year study period was 31–35 % for inpatient cases and 67–72 % for outpatient cases, with no marked changes over the years.

Conclusions

The proportion of inpatients receiving short-course treatments for CAP was low. In Japan, especially for inpatient cases, further efforts are required to optimize the duration of CAP treatment.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection and Chemotherapy INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY

CiteScore

4.10

自引率

4.50%

发文量

303

审稿时长

47 days

期刊介绍： The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.